trial

Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study

NCTId NCT01133080
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Unknown
Enrollment 50 (estimated)
Sponsored by Shalvata Mental Health Center
Primary completion 2013-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Unknown
Enrollment
50 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2010-06
Primary completion
2013-01
Eligibility
ALL · 20 Years · 65 Years

Interventions & indications

Drugs
Minocycline

Sponsors

Shalvata Mental Health CenterLead Sponsor

Investigators

1
Yechiel Levkovitz, MD, PhDPrincipal Investigator

Sites

2 total
Hod HaSharon, IsraelHod HaSharon, Israel

Facts & assertions

4 sourced
Enrollment
50
Phase
PHASE4
Primary Completion Date
2013-01
Status
UNKNOWN
relationships
The graph out of here
drug
Minocycline
drug
lead_sponsor
Shalvata Mental Health Center
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Yechiel Levkovitz, MD, PhD
person